Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback